Long-term safety of tofersen for SOD1 ALS in China
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests the long-term safety of an investigational drug called tofersen (Qalsody) for people in China who have a specific type of ALS caused by a change in the SOD1 gene. If you qualify, you will receive the drug and be monitored for side effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have ALS caused by a change in the SOD1 gene.
- If you take riluzole, you must be on a steady dose for at least 30 days before starting the study and stay on that dose.
- If you take edaravone, you must have been on it for at least 60 days before starting and continue on a steady dose unless your doctor says to stop.
- Women who can become pregnant must use effective birth control during the study.
- You cannot have taken tofersen before, or any treatment with stem cells, gene therapy, or RNA interference.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.
This study checks the long-term safety of the drug tofersen (also known as Qalsody) for people with a specific genetic type of ALS caused by SOD1 mutations. It aims to make sure the drug is safe over time by watching participants from registry networks.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests a single injection of a gene therapy called INS1202 into the spinal fluid. It is for people with ALS, including those with a specific genetic form (SOD1 mutation). The goal is to see if it is safe and how it affects the body.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.